EP Patent

EP3900726A1 — Compositions and methods for treatment of abnormal cell growth

Assigned to Pfizer Inc · Expires 2021-10-27 · 5y expired

What this patent protects

This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.

USPTO Abstract

This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.

Drugs covered by this patent

Patent Metadata

Patent number: EP3900726A1
Jurisdiction: EP
Classification: —
Expires: 2021-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.